Company Filing History:
Years Active: 2023-2025
Title: Abdellatif El Marrouni: Innovator in HIV Treatment
Introduction
Abdellatif El Marrouni is a notable inventor based in Ambler, PA (US). He has made significant contributions to the field of medical science, particularly in the development of treatments for HIV. His innovative work focuses on creating selective cytotoxic agents that target HIV-infected cells.
Latest Patents
El Marrouni holds a patent for "Tetrahydroquinazoline derivatives as selective cytotoxic agents." This patent describes tetrahydroquinazoline derivatives of Formula I and their application in selectively killing HIV-infected GAG-POL expressing cells. Importantly, this method does not cause cytotoxicity to HIV-naïve cells. The invention aims to provide treatment or prophylaxis for HIV infection and to delay the onset or progression of AIDS or AIDS Related Complex (ARC). He has 1 patent to his name.
Career Highlights
Abdellatif El Marrouni is associated with Merck Sharp & Dohme Corporation, a leading global healthcare company. His work at Merck has allowed him to contribute to groundbreaking research and development in the pharmaceutical industry.
Collaborations
El Marrouni has collaborated with esteemed colleagues, including Antonella Converso and Anthony W Shaw. These partnerships have enhanced the research and development efforts in the field of HIV treatment.
Conclusion
Abdellatif El Marrouni's innovative work in developing selective cytotoxic agents represents a significant advancement in the fight against HIV. His contributions continue to impact the medical community and offer hope for improved treatment options.